about
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology:European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (ConstituteUniversal definition of myocardial infarction: Kristian Thygesen, Joseph S. Alpert and Harvey D. White on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial InfarctionACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationHow long should angiotensin-converting enzyme inhibitors be given to patients following myocardial infarction: implications of the HOPE trialELITE II and Val-HeFT are different trials: together what do they tell us?Recommendations on pre-hospital and early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of AcademicRelation between renal dysfunction and cardiovascular outcomes after myocardial infarctionEffect of nesiritide in patients with acute decompensated heart failureESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with theIncreased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failureThe data monitoring experience in the MOXCON trial.Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology.Universal definition of myocardial infarction.Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan.The homeostatic chemokine CCL21 predicts mortality and may play a pathogenic role in heart failure.Cardiac-resynchronization therapy in heart failure with a narrow QRS complex.New devices in heart failure: an European Heart Rhythm Association report: developed by the European Heart Rhythm Association; endorsed by the Heart Failure Association.Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology.Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction.ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of CardioloEuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population.Moderate alcohol consumption is associated with reduced long-term cardiovascular risk in patients following a complicated acute myocardial infarction.2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with theESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with theThe impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HFDiagnosis and assessment of the heart failure patient: the cornerstone of effective management.Renal function estimation and Cockroft-Gault formulas for predicting cardiovascular mortality in population-based, cardiovascular risk, heart failure and post-myocardial infarction cohorts: The Heart 'OMics' in AGEing (HOMAGE) and the high-risk myocIntracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial.The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study.Left bundle branch block as a risk factor for progression to heart failure.Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology.European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituteEuropean guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by repOverview of emerging pharmacologic agents for acute heart failure syndromes.Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial.
P50
Q22242892-23C0DD97-14C3-4F09-AA14-178119738DDBQ22242896-03589C86-D459-4481-B58F-F3E582E48475Q22242898-103C494A-708B-4D69-AFD3-5704E915158DQ22242900-43361C82-7A10-49B4-B219-FDEEC00EF846Q22306351-1D3345CF-2745-478E-89F1-EDE7FC0E2AD4Q24793341-CD49D212-A941-400D-9681-FB386F74C457Q24806894-10DC16C4-2F02-4098-93C7-8D39C141D0D8Q27008175-7E7297D5-E62C-4A35-A897-564DF9B87620Q28213597-8FCDA418-718F-494D-96FA-5984D3A6797AQ28242547-15CED3F6-9BEB-4AC2-A0AF-D6FFF213C098Q28267062-C21D3030-AF96-4198-846A-20357DFBE31BQ28575465-EE9C502E-8438-4E6B-B77F-04EC9D347143Q30975995-C62B9850-4117-4046-B490-B5F05BB6CB3FQ33433326-5B6858B0-55DC-4FE1-9E08-7673F32230E6Q33996248-11833561-31F4-46A0-A442-889D72C62181Q34007701-E97D4693-5F8F-41E5-AFF7-EEFA9F9A5A69Q34150300-8D26AE71-01AA-4FDF-B0F4-4A8949DD97C9Q34200352-69F1FEFF-401C-436D-B656-180EB5316231Q34368183-36F409FA-79B0-4A8D-A6F7-19259193DC94Q34387086-CD502744-BFC8-4725-83AA-46D160FC48BFQ34389554-F458FC3C-962F-49CB-ADB6-67C5B1B94661Q34533036-8D388CA6-5DBA-4843-A47D-D26F8CB48E5EQ34560910-7E2CFD25-5426-4293-A3B5-F5C6DABD6292Q34568746-326FDDD2-2CD0-4B2C-AEE4-5D4DBFA546A8Q34589779-0DC2D799-F938-4335-A562-5321163A68AAQ34636529-DC3369B5-7E37-4F4F-8DE8-F46D4DC81748Q34640762-E980F1C4-0B43-4528-ABE2-73D79C0EE03DQ34830023-4CF3B278-06F3-4905-8D08-1618D3D16077Q35549440-EB253C36-C8E9-4B63-BA1C-08B0D6F42919Q35684955-420014B1-1390-41CC-9359-C2A4D16C3242Q36046578-D7C5E12F-4840-40B7-A9D1-6F64AAB521C3Q36188016-8111E1B7-5615-4FA7-9336-904B9C2756D7Q36353619-23899CFD-438C-4921-B4CA-4AA7F726F3FCQ36499172-17CAC3C8-7E5B-468B-B24C-47FD6BF0873FQ36557107-3D2904E8-BDD8-4DFE-8C2B-110AA16228E8Q36811824-45C1F8DF-77FD-4254-B692-6DCC39CE2033Q36921887-C1B9648F-AE6F-479C-9318-DC11E71B52D9Q36921892-4057E482-FEAB-4806-9411-F0E5E09299FDQ37086309-37C9F20E-6C15-4D09-B76D-30DBA9872CE0Q37250239-93AF6412-6B10-4074-BB7A-3F8E69C0273B
P50
description
Amerikaans onderzoeker
@nl
forsker ved UiB
@nb
hulumtues
@sq
researcher
@en
name
Kenneth Dickstein
@ast
Kenneth Dickstein
@da
Kenneth Dickstein
@de
Kenneth Dickstein
@en
Kenneth Dickstein
@es
Kenneth Dickstein
@fr
Kenneth Dickstein
@nb
Kenneth Dickstein
@nl
Kenneth Dickstein
@nn
Kenneth Dickstein
@sl
type
label
Kenneth Dickstein
@ast
Kenneth Dickstein
@da
Kenneth Dickstein
@de
Kenneth Dickstein
@en
Kenneth Dickstein
@es
Kenneth Dickstein
@fr
Kenneth Dickstein
@nb
Kenneth Dickstein
@nl
Kenneth Dickstein
@nn
Kenneth Dickstein
@sl
prefLabel
Kenneth Dickstein
@ast
Kenneth Dickstein
@da
Kenneth Dickstein
@de
Kenneth Dickstein
@en
Kenneth Dickstein
@es
Kenneth Dickstein
@fr
Kenneth Dickstein
@nb
Kenneth Dickstein
@nl
Kenneth Dickstein
@nn
Kenneth Dickstein
@sl